---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-010790"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-05-15T13:25:40+00:00"
generated_at: "2026-05-15T13:28:58.582408+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix reports Phase 1 PK data for TNX-4800 Lyme antibody; two-dose regimen supports 6-month protection

## Summary
- TNX-4800 Phase 1 PK data presented at Global Lyme Alliance; two-dose 350 mg SC regimen (Day 1, Day 56) modeled.
- Simulations predict days above MEC: 10 µg/mL (196 days), 15 µg/mL (161 days), 20 µg/mL (136 days), 5 µg/mL (265 days).
- Data supports maintaining serum level above 10 µg/mL for six months after initial dose, proposed Phase 2 primary endpoint.
- Adaptive Phase 2 field study planned for first half of 2027, pending FDA agreement.

## SEC filing metadata
- accession: 0001999371-26-010790
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-05-15T13:25:40+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010790/0001999371-26-010790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126010790/tnxp-8k_051526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-010790
- JSON: https://secwatch.observer/filing/0001999371-26-010790.json
- Plain text: https://secwatch.observer/filing/0001999371-26-010790.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.